

## REFERENCES

- Arcila, M. E., Nafa, K., Chaft, J. E., Rekhtman, N., Lau, C., Reva, B. A., ... Ladanyi, M. (2013). EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics. *Mol Cancer Ther*, *12*(2), 220–229.  
<https://doi.org/10.1016/j.asieco.2008.09.006.EAST>
- Barber, E. A., & Reckamp, K. L. (2016). Best Initial Treatment Strategies for EGFR -Mutant Lung Cancer. *Americal Journal of Hematology/Oncology*, *12*(12), 4–7.
- Bessetti, J. (2007). An Introduction to PCR Inhibitors. *Promega Corporation*, 9–10.
- Bio-Rad. (n.d.). PCR Troubleshooting. Retrieved June 18, 2018, from <http://www.bio-rad.com/en-sg/applications-technologies/pcr-troubleshooting?ID=LUSO3HC4S>
- Brownie, J., Shawcross, S., Theaker, J., Whitcombe, D., Ferrie, R., Newton, C., & Little, S. (1997). The elimination of primer-dimer accumulation in PCR. *Nucleic Acids Research*, *25*(16), 3235–3241.  
<https://doi.org/10.1093/nar/25.16.3235>
- Derakhshandeh, P. (2015). Reverse Dot Blot. Retrieved from  
[https://www.google.co.id/url?sa=t&rct=j&q=&esrc=s&source=web&cd=6&cad=rja&uact=8&ved=0ahUKEwivrsWy04bXAhUBwI8KHQJKClkQFghLMAU&url=http%3A%2F%2Fmedicine.tums.ac.ir%3A804%2FUsers%2Fpopak\\_derakhshandeh%2FReverse%2520Dot%2520Blot-short.ppt&usg=AOvVaw2dynwtp7U](https://www.google.co.id/url?sa=t&rct=j&q=&esrc=s&source=web&cd=6&cad=rja&uact=8&ved=0ahUKEwivrsWy04bXAhUBwI8KHQJKClkQFghLMAU&url=http%3A%2F%2Fmedicine.tums.ac.ir%3A804%2FUsers%2Fpopak_derakhshandeh%2FReverse%2520Dot%2520Blot-short.ppt&usg=AOvVaw2dynwtp7U)
- El-Telbany, A., & Ma, P. C. (2012). Cancer genes in lung cancer: racial disparities: are there any? *Genes & Cancer*, *3*(7–8), 467–80. <https://doi.org/10.1177/1947601912465177>
- Feng, H., Wang, X., Zhang, Z., Tang, C., Ye, H., Jones, L., ... Liu, D. (2015). Identification of Genetic Mutations in Human Lung Cancer by Targeted Sequencing. *Cancer Informatics*, *14*, 83–93.  
<https://doi.org/10.4137/CIN.S22941>
- Ferlay, J., Soerjomataram, I., Ervik, M., Dikshit, R., Eser, S., Mathers, .C, ... Bray, F. (2012). Lung Cancer Estimated Incidence, Mortality and Prevalence Worldwide in 2012. Retrieved March 19, 2018, from [http://globocan.iarc.fr/Pages/fact\\_sheets\\_cancer.aspx](http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx)
- Gold, B. (2003). Origin and utility of the reverse dot-blot. *Expert Review of Molecular Diagnostics*, *3*(2), 143–52. <https://doi.org/10.1586/14737159.3.2.143>
- Hartmann, J., Haap, M., Kopp, H.-G., & Lipp, H.-P. (2009). Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects. *Current Drug Metabolism*, *10*(5), 470–481.  
<https://doi.org/10.2174/138920009788897975>
- Henegariu, O. (2009). Troubleshooting for PCR and multiplex PCR. Retrieved June 18, 2018, from <http://info.med.yale.edu/genetics/ward/tavi/Trblesht.html>
- Jain, A., Tindell, C. A., Laux, I., Hunter, J. B., Curran, J., Galkin, A., ... Agus, D. B. (2005). Epithelial membrane protein-1 is a biomarker of gefitinib resistance. *Proceedings of the National Academy of Sciences of the United States of America*, *102*(33), 11858–63.  
<https://doi.org/10.1073/pnas.0502113102>
- Lee, V. H. F., Tin, V. P. C., Choy, T. S., Lam, K. O., Choi, C. W., Chung, L. P., ... Wong, M. P. (2013). Association of exon 19 and 21 EGFR mutation patterns with treatment outcome after first-line tyrosine kinase inhibitor in metastatic non-small-cell lung cancer. *Journal of Thoracic Oncology*, *8*(9), 1148–1155. <https://doi.org/10.1097/JTO.0b013e31829f684a>
- Lemjabbar-alaoui, H., Hassan, O., Yang, Y., Buchanan, P., Division, T. O., & Francisco, S. (2015). Lung cancer: biology and treatment options. *Biochim Biophys Acta*, *1856*(2), 189–210.  
<https://doi.org/10.1016/j.bbcan.2015.08.002.Lung>

- Lovly, C., Horn, L., & Pao, W. (2018). Molecular Profiling of Lung Cancer. Retrieved March 19, 2018, from <https://www.mycancergenome.org/content/disease/lung-cancer/>
- Lovly, C. M., Horn, L., & William, P. (2015). EGFR in Non-Small Cell Lung Cancer (NSCLC) - My Cancer Genome. Retrieved August 22, 2017, from <https://www.mycancergenome.org/content/disease/lung-cancer/egfr/>
- Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., ... Nukiwa, T. (2010). Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR. *New England Journal of Medicine*, 362(25), 2380–2388. <https://doi.org/10.1056/NEJMoa0909530>
- Maher, M., Lahiff, S., & Morris, D. (2006). Molecular Diagnostics and Epidemiological Typing Methods for Common Foodborne Pathogens *Campylobacter* and *Salmonella*. In J. R. Rao, C. C. Fleming, & J. E. Moore (Eds.), *Molecular Diagnostics: Current Technology and Applications* (p. 98). Horizon Bioscience. Retrieved from [https://books.google.co.id/books?id=En1gGH3TNkIC&pg=PA98&lpg=PA98&dq=biodyne+c+membrane+activation+principle&source=bl&ots=DmUCD63mlm&sig=XJWiK5Irl2SLR-Q6bL9tWCxD0VU&hl=en&sa=X&ved=0ahUKEwjOn6ynh\\_TbAhVPcCsKHYL4BRgQ6AEISDAF#v=onepage&q=biodyne c membra](https://books.google.co.id/books?id=En1gGH3TNkIC&pg=PA98&lpg=PA98&dq=biodyne+c+membrane+activation+principle&source=bl&ots=DmUCD63mlm&sig=XJWiK5Irl2SLR-Q6bL9tWCxD0VU&hl=en&sa=X&ved=0ahUKEwjOn6ynh_TbAhVPcCsKHYL4BRgQ6AEISDAF#v=onepage&q=biodyne%20c%20membra)
- Markoulatos, P., Siafakas, N., & Moncany, M. (2002). Multiplex polymerase chain reaction: A practical approach. *Journal of Clinical Laboratory Analysis*, 16(1), 47–51. <https://doi.org/10.1002/jcla.2058>
- Michael A. Innis, David H. Gelfand, & John J. Sninsky (Eds.). (1999). *PCR applications : protocols for functional genomics*. Academic Press. Retrieved from [https://books.google.co.id/books?id=9aOMfPFHO1EC&pg=PA91&dq=multiplex+pcr+troubleshooting&hl=en&sa=X&ved=0ahUKEwjHl\\_v5kN3bAhVFi1kKHTXrBFQQ6AEIMTAC#v=onepage&q=multiplex pcr troubleshooting&f=false](https://books.google.co.id/books?id=9aOMfPFHO1EC&pg=PA91&dq=multiplex+pcr+troubleshooting&hl=en&sa=X&ved=0ahUKEwjHl_v5kN3bAhVFi1kKHTXrBFQQ6AEIMTAC#v=onepage&q=multiplex%20pcr%20troubleshooting&f=false)
- Midha, A., Dearden, S., & McCormack, R. (2015). EGFR mutation incidence in non-Small-cell lung cancer of adenocarcinoma histology: A systematic review and global map by ethnicity (mutMapII). *American Journal of Cancer Research*, 5(9), 2892–2911. <https://doi.org/10.5194/hess-11-1609-2007>
- Molina, J. R., Yang, P., Cassivi, S. D., Schild, S. E., & Adjei, A. A. (2008). Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship. *Mayo Clin Proc.*, 83(5)(May), 584–594. <https://doi.org/10.1007/s11103-011-9767-z>.Plastid
- Nan, X., Xie, C., Yu, X., & Liu, J. (2017). EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer. *Oncotarget*, 8(43), 75712–75726. <https://doi.org/10.18632/oncotarget.20095>
- QIAGEN. (n.d.). Online User-Guide MultiPlex PCR. Retrieved June 18, 2018, from <https://www.qiagen.com/media/product-tools/multiplex-pcr-web/index.html>
- QIAGEN. (2010a). HotStarTaq® PCR Handbook.
- QIAGEN. (2010b). Multiplex PCR Handbook.
- Rådström, P., Knutsson, R., Wolffs, P., Lövenklev, M., & Löfström, C. (2004). Pre-PCR Processing. *Molecular Biotechnology*, 26.
- Ridge, C. A., McErlean, A. M., & Ginsberg, M. S. (2013). Epidemiology of Lung Cancer. *Semin Intervent Radiol*, 30, 93–98. <https://doi.org/http://dx.doi.org/10.1055/s-0033-1342949>.
- Shao, W., Khin, S., & Kopp, W. C. (2012). Characterization of Effect of Repeated Freeze and Thaw Cycles on Stability of Genomic DNA Using Pulsed Field Gel Electrophoresis. *Biopreservation and Biobanking*, 10(1), 4–11. <https://doi.org/10.1089/bio.2011.0016>

- Shum, J., & Paul, N. (2009). Chemically modified primers for improved multiplex PCR. *Anal Biochem*, *19*(2), 389–399. <https://doi.org/10.1016/j.asieco.2008.09.006.EAST>
- Sordella, R., Bell, D. W., Haber, D. A., & Settleman, J. (2004). Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways. *Science*, *305*(5687), 1163–1167. <https://doi.org/10.1126/science.1101637>
- Su, K. Y., Chen, H. Y., Li, K. C., Kuo, M. L., Yang, J. C. H., Chan, W. K., ... Yang, P. C. (2012). Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. *Journal of Clinical Oncology*, *30*(4), 433–440. <https://doi.org/10.1200/JCO.2011.38.3224>
- Sullivan, I., & Planchard, D. (2017). Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line. *Frontiers in Medicine*, *3*(January), 1–13. <https://doi.org/10.3389/fmed.2016.00076>
- Syahruddin, E., Sri, N., Rima, A., Soeroso, N., Levi, M., & Hidajat, H. (2018). Uncommon EGFR mutations in cytological specimens of 1 , 874 newly diagnosed Indonesian lung cancer patients, 25–34.
- The Cancer Atlas, & American Cancer Society. (2012). The Burden of Cancer. Retrieved October 23, 2017, from <http://canceratlas.cancer.org/the-burden/the-burden-of-cancer/>
- Toh, C. K., Gao, F., Lim, W. T., Leong, S. S., Fong, K. W., Yap, S. P., ... Tan, E. H. (2007). Differences between small-cell lung cancer and non-small-cell lung cancer among tobacco smokers. *Lung Cancer*, *56*(2), 161–166. <https://doi.org/10.1016/j.lungcan.2006.12.016>
- Wagner, A., Blackstone, N., Cartwright, P., Dick, M., Misof, B., Snow, P., ... Pendleton, J. (1994). Surveys of Gene Families using Polymerase Chain Reaction: PCR Selection and PCR Drift. *Systematic Biology*, *43*(2), 250–261. <https://doi.org/https://doi.org/10.1093/sysbio/43.2.250>
- Wong, M. C. S., Lao, X. Q., Ho, K., Goggins, W. B., & Tse, S. L. A. (2017). Incidence and mortality of lung cancer : global trends and association with socioeconomic status. *Scientific Reports*, (October), 1–9. <https://doi.org/10.1038/s41598-017-14513-7>
- World Health Organization. (2014). Cancer Country Profiles: Indonesia. *Cancer Country Profiles*, 22–23.
- Yatabe, Y., Kerr, K. M., Utomo, A., Rajadurai, P., Tran, V. K., Du, X., ... Mok, T. (2015). EGFR mutation testing practices within the Asia pacific region: Results of a multicenter diagnostic survey. *Journal of Thoracic Oncology*, *10*(3), 438–445. <https://doi.org/10.1097/JTO.0000000000000422>
- Yun Ha, S., Choi, S.-J., Ho Cho, J., Joo Choi, H., Lee, J., Jung, K., ... Kim, J. (2015). Lung cancer in never-smoker Asian females is driven by oncogenic mutations, most often involving EGFR. *Oncotarget*, *6*(7), 5465–5474. <https://doi.org/10.18632/oncotarget.2925>
- Zappa, C., & Mousa, S. A. (2016). Non-small cell lung cancer: current treatment and future advances. *Translational Lung Cancer Research*, *5*(3), 288–300. <https://doi.org/10.21037/tlcr.2016.06.07>